Budak-Alpdogan T - Search Results

1

Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.

Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR. Capiaux GM, et al. Cancer Gene Ther. 2004 Dec;11(12):767-73. doi: 10.1038/sj.cgt.7700683. Cancer Gene Ther. 2004. PMID: 15359285

2

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.

Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Banerjee D, et al. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73. doi: 10.1016/s0925-4439(02)00079-0. Biochim Biophys Acta. 2002. PMID: 12084458 Free article. Review.

3

Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil.

Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, Bertino JR. Capiaux GM, et al. Hum Gene Ther. 2003 Mar 20;14(5):435-46. doi: 10.1089/104303403321467207. Hum Gene Ther. 2003. PMID: 12691609

4

Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.

Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR. Budak-Alpdogan T, et al. Mol Ther. 2004 Sep;10(3):574-84. doi: 10.1016/j.ymthe.2004.06.115. Mol Ther. 2004. PMID: 15336657 Free article.

5

Hematopoietic stem cell gene therapy with drug resistance genes: an update.

Budak-Alpdogan T, Banerjee D, Bertino JR. Budak-Alpdogan T, et al. Cancer Gene Ther. 2005 Nov;12(11):849-63. doi: 10.1038/sj.cgt.7700866. Cancer Gene Ther. 2005. PMID: 16037821 Review.

6

Role of pemetrexed in non-small cell lung cancer.

Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR. Longo-Sorbello GS, et al. Cancer Invest. 2007 Feb;25(1):59-66. doi: 10.1080/07357900601130748. Cancer Invest. 2007. PMID: 17364559 Review.

7

Chemoprotection by transfer of resistance genes.

Budak-Alpdogan T, Bertino JR. Budak-Alpdogan T, et al. Methods Mol Biol. 2009;542:661-704. doi: 10.1007/978-1-59745-561-9_34. Methods Mol Biol. 2009. PMID: 19565927

8

Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells.

Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J. Mayer-Kuckuk P, et al. Cell Transplant. 2006;15(1):75-82. doi: 10.3727/000000006783982278. Cell Transplant. 2006. PMID: 16700332 Free article.

9

Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol.

Budak-Alpdogan T, Przybylowski M, Gonen M, Sadelain M, Bertino J, Rivière I. Budak-Alpdogan T, et al. Hum Gene Ther. 2006 Jul;17(7):780-94. doi: 10.1089/hum.2006.17.780. Hum Gene Ther. 2006. PMID: 16839276

10

Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D. Barboza NM, et al. Cancer Biol Ther. 2012 Jan 15;13(2):114-22. doi: 10.4161/cbt.13.2.18876. Cancer Biol Ther. 2012. PMID: 22336911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters